TY - JOUR
T1 - Physiologic insights from the COPD genetic epidemiology study
AU - Stringer, William W.
AU - Porszasz, Janos
AU - Bhatt, Surya P.
AU - McCormack, Meredith C.
AU - Make, Barry J.
AU - Casaburi, Richard
N1 - Funding Information:
Abbreviations: COPD Genetic Epidemiology, COPDGene; chronic obstructive pulmonary disease, COPD; computed tomography, CT; asthma-COPD overlap syndrome, ACO; forced expiratory volume in 1 second, FEV1; forced vital capacity, FVC; Preserved Ratio Impaired Spirometry, PRISm; 6-minute walk test, 6MW; forced expiratory volume in 6 second, FEV6; lower limit normal, LLN; low attenuation area, LAA; Hounsfield units, HU; St George’s Respiratory Questionnaire, SGRQ; modified Medical Research Council, mMRC; Global Lung Initiative, GLI; body mass index, BMI; bronchodilator response, BDR; acute exacerbation of COPD, AECOPD; prebronchodilator obstruction, PREO; postbronchodilator obstruction, POSTO; prebronchodilator obstruction not present, PREN; postbronchodilator obstruction not present, POSTN; Body mass index-airway Obstruction-Dyspnea-Exercise, BODE Funding Support: The COPDGene® project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens and Sunovion. Date of Acceptance: April 18, 2019 Citation: Stringer WW, Porszasz J, Bhatt SP, McCormack MC, Make BJ, Casaburi R. Physiologic insights from the COPD Genetic Epidemiology study. Chronic Obstr Pulm Dis. 2019;6(3):256-266. doi: https://doi.org/10.15326/jcopdf.6.3.2019.0128
Funding Information:
WWS reports research grants from Boehringer Ingelheim, AstraZeneca, Astellas and consulting with Allergan and Syneos Health. SPB has received research grants from the National Institutes of Health (K23HL133438) and from ProterixBio. He has served on advisory boards for Sunovion and GlaxoSmithKline. MCM reports royalties for authorship from UpToDate and consulting with GlaxoSmithKline. BJM reports consulting agreements and/or grant funding and/ or advisory board service for AstraZeneca, the National Heart Lung and Blood Institute, Spiration, GlaxoSmithKline, Sunovion, Pearl, Verona, Boehringer Ingelheim, Theravance, Circassia, Third Pole, Shire, and Phillips. RC reports research grants from Boehringer Ingelheim, Astra Zeneca, Astellas, Glaxo SmithKline; service on advisory boards from Boehringer Ingelheim, GlaxoSmithKline; consulting for Regeneron, Genetech; speakers bureau for Boehringer Ingelheim, Astra Zeneca and GlaxoSmithKline. JP has nothing to declare.
Funding Information:
The COPDGene? project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens and Sunovion.
Publisher Copyright:
© 2019 COPD Foundation. All rights reserved.
PY - 2019
Y1 - 2019
N2 - COPD Genetic Epidemiology Study (COPDGene®) manuscripts have provided important insights into chronic obstructive pulmonary disease (COPD) pathophysiology and outcomes, including a better understanding of COPD phenotypes relating computed tomography (CT) anatomic data to spirometric and patient-reported outcomes. Spirometry significantly underdiagnoses smoking-induced lung disease, and there is a marked improvement in sensitivity and specificity with CT scanning. This review also highlights the COPDGene® exploration of specific spirometry phenotypes (e.g.,PRISm), contributors to spirometric decline, composite physiologic measures, asthma-COPD overlap (ACO) syndrome, consequences of bronchodilator responsiveness, newer methods to assess small airway dysfunction, and spirometric correlates of comorbid diseases such as obesity and diabetes.
AB - COPD Genetic Epidemiology Study (COPDGene®) manuscripts have provided important insights into chronic obstructive pulmonary disease (COPD) pathophysiology and outcomes, including a better understanding of COPD phenotypes relating computed tomography (CT) anatomic data to spirometric and patient-reported outcomes. Spirometry significantly underdiagnoses smoking-induced lung disease, and there is a marked improvement in sensitivity and specificity with CT scanning. This review also highlights the COPDGene® exploration of specific spirometry phenotypes (e.g.,PRISm), contributors to spirometric decline, composite physiologic measures, asthma-COPD overlap (ACO) syndrome, consequences of bronchodilator responsiveness, newer methods to assess small airway dysfunction, and spirometric correlates of comorbid diseases such as obesity and diabetes.
KW - Asthma-COPD overlap
KW - COPD
KW - COPD Genetic Epidemiology
KW - COPDGene
KW - Chronic obstructive pulmonary disease
KW - PRISm
KW - Preserved Ratio Impaired Spirometry
UR - http://www.scopus.com/inward/record.url?scp=85073896097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073896097&partnerID=8YFLogxK
U2 - 10.15326/jcopdf.6.3.2019.0128
DO - 10.15326/jcopdf.6.3.2019.0128
M3 - Review article
C2 - 31342731
AN - SCOPUS:85073896097
VL - 6
SP - 256
EP - 266
JO - Chronic Obstructive Pulmonary Diseases
JF - Chronic Obstructive Pulmonary Diseases
SN - 2372-952X
IS - 3
ER -